Navigation Links
MAP Pharmaceuticals to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
Date:6/4/2008

MOUNTAIN VIEW, Calif., June 4 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference on Tuesday, June 10, 2008, at 4:00 pm (PT) in Dana Point, California.

A live webcast of the presentation will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay will also be available within 24 hours for seven days following the presentation.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from chronic conditions that it believes are not adequately treated by currently available medicines. The Company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004, in late stage development for the potential treatment of pediatric asthma and migraine respectively. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
2. Antipodean Pharmaceuticals Announces FDA Acceptance of IND for MitoQ(R)
3. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
4. Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
5. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
6. Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
7. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
8. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
9. Watson to Present at the UBS Global Specialty and Generic Pharmaceuticals Conference
10. Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference
11. DURECT Corporation Presenting at the 2008 UBS Global Generic and Specialty Pharmaceuticals Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s ... ostomy patients, standing as living proof that attitude and determination can combine into ... issues that spike around the holidays. This campaign will offer patients a new-found ...
(Date:12/2/2016)... Hawaii (PRWEB) , ... December 02, 2016 , ... ... 2016 at the Hyatt Regency Waikiki Beach Resort and Spa in Honolulu, offering ... in the field of pain management. , The demand for supplemental training ...
(Date:12/2/2016)... Viejo, California (PRWEB) , ... December 02, 2016 , ... ... will allow FCPX editors to create versatile lower third titles with just a few ... , Pro3rd Accents Volume 2 includes 30 lower third animations. Choose from various styles ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ‘Tis the season ... of $1,000 each from the National Family Partnership and the Drug Enforcement Administration as ... decorated their homes and the 10 winning schools who decorated their campuses with this ...
(Date:11/30/2016)... ... November 30, 2016 , ... Center For ... announced the opening of a new eating disorder treatment center location in Palm ... for adults and adolescents, both males and females ages 10 and older with ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2, 2016 In the first ever attempt ... those derived from C. sativa, the Hebrew University in ... Napoli Federico II , the Universita` del Piemonte Orientale ... critical, integrated and unified inventory of phytocannabinoids of different ... on the remarkable chemical and structural diversity of phytocannabinoids. ...
(Date:12/2/2016)... Columbia , December 2, 2016 bioLytical Laboratories, ... INSTI HIV-Selbsttest, bei den Mitgliedern des Apothekenbundes von Kenia eingeführt. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ...
(Date:12/2/2016)... 2016   CytoSorbents Corporation (NASDAQ: CTSO ... Union approved CytoSorb ® cytokine adsorber to treat ... announced that Dr. Phillip Chan , Chief Executive ... Micro Main Event investor conference held from December ... Sunset Boulevard Hotel in Los Angeles, California ...
Breaking Medicine Technology: